# AMIDE DERIVATIVES AND 5 LIPOXYGENASE INHIBITORS CONTAINING THE SAME AS AN ACTIVE INGREDIENT

## Claims
Amidderivat der allgemeinen Formel I

## Description
The present invention relates to novel amide derivatives and 5 lipoxygenase inhibitors containing the same as an active ingredient. The amide derivatives provided by the invention possess activities inhibiting 5 lipoxygenase which is an enzyme. Leucotrienes such as leucotriene C₄ LTC₄ and leucotriene D₄ LTD₄ which are allergy inducing factors are biosynthesized It has recently been found that action of 5 lipoxygenase on arachidonic acid results in formation of leucotrienes which are allergy inducing factors Science vol. 220, page 568, 1983, published by the American Association for the Advancement of Science . As described above, leucotrienes such as LTC₄ and LTD₄ which are 5 lipoxygenase products from arachidonic acid are important factors participating in onset of diseases such as allergic asthma and allergic rhinitis, and therefore, development of drugs that are of 5 lipoxygenase inactivating activities and capable of inhibiting its action is strongly desired. From US A 4,070,484, US A 4,337,270, Chemical Abstracts, volume 94, no. 21, May 1981, page 686, n 174666c, Chemical Abstracts, volume 92, no. 19, May 1980, page 578, n 163724c, Chemical Abstracts, volume 85, no. 13, May 1976, page 497, n 89843g, CH A 345 016 and Chemical Abstracts, volume 102, no. 25, June 1985, page 565, n 220592j there are already known aromatic carboxamides which are said to exhibit various pharmacological effects, i. a. antiallergic effects. As a results of studies on the synthesis of amide derivatives and their 5 lipoxygenase inhibiting activities, we have found that the amide derivatives according to the present invention possess high 5 lipoxygenase inhibiting activities. The invention has been completed based upon such finding. It is an object of the invention to provide novel amide derivatives and 5 lipoxygenase inhibitors containing the same as an active ingredient. According to the present invention, there are provided amide derivatives having the general formula In the formula I , R¹ represents hydrogen atom or an alkyl group with 1 to 4 carbon atom s , R² represents hydrogen atom, an alkyl group with 1 to 4 carbon atom s or toluoyloxy group, or R¹ and R² when taken together represent an alkylene group with 1 to 3 carbon atom s , R³ represents hydrogen atom or an alkoxy group with 1 to 4 carbon atom s , R² and R³ both being hydrogen atom when R¹ represents hydrogen atom, and n is an integer of 1 or 2 Y represents an amino group having the formula wherein p is an integer from 2 to 4. Further according to the invention, 5 lipoxygenase inhibitors containing as an active ingredient an amide derivative having the above described general formula I are provided. In the definitions of the above formula, the alkyl group containing 1 4 carbon atoms is for example methyl, ethyl, n propyl, isopropyl, n butyl or isobutyl. The alkoxy group containing 1 4 carbon atoms is for example methoxy, ethoxy, n propoxy, isopropoxy, n butoxy or isobutoxy. The alkylene group containing 1 3 carbon atoms is for example methylene, ethylene, trimethylene or 1 methylethylene. The amide derivatives having the above formula I are novel compounds which are produced, for example, by reacting a carboxylic acid having the formula wherein R¹, R² wherein R¹, R², R³ and n are as defined above with an amine having the formula wherein Y is as defined above and, if required, subjecting the reaction product to a deprotection reaction. The amide derivatives of the invention are useful as 5 lipoxygenase inhibitors or antiallergic agents. The dosage will generally be in the range from 30 to 200 mg and preferably from 50 to 600 mg per day in adults, although it is variable depending upon of the patient. It may be divided into one to three doses per day as required depending upon conditions of the patient. The administration may be by any suitable route. Intravenous injection is applicable, though oral administration is particularly desirable. The compounds of the invention may be blended with pharmaceutical carriers or excipients and formulated into a variety of forms such as tablets, sugar coated tablets, powders, capsules, granules, suspension, emulsion or injectable solution. As examples of the carrier or excipient are mentioned calcium carbonate, starch, glucose, lactose, dextrin, arginic acid, mannitol, talc and magnesium stearate. Examples and Test Example will be given below to describe the invention in more details. A mixture of 5.71 g 56.5 mmol of 4 hydroxypiperidine and 5.28 g 20.8 mmol of N 2 bromoethyl phthalimide was reacted at 150 C for 1 hour under argon atmosphere. The reaction mixture was allowed to cool, water was added, and then the mixture was extracted with chloroform. The organic layer was concentrated by evaporation under reduced pressure and the residue was subjected to silica gel column chromatography, eluted with chloroform methanol 20 1 , to give 3.60 g 13.1 mmol of 1 2 phthaloylaminoethyl 4 hydroxypiperidine. To 3.60 g 13.1 mmol of the alcohol compound were added 10 ml 56.3 mmol of benzhydryl chloride and 3.47 g 25.1 mmol of potassium carbonate, and the mixture was reacted at 135 To a solution of 224 mg 0.509 mmol of the piperidine compound in ethanol 5 ml was added, under argon atmosphere, 50 mg 0.999 mmol of hydrazine hydrate, and the mixture was refluxed for 1 hour, after which it was concentrated by evaporation under reduced pressure. To the residue was added 2 ml of dry dimethylformamide. A solution of 527 mg 1.37 mmol of N 3 3 methoxy 4 β methoxyethoxymethoxy phenyl 2 propenoyl thiazolidine 2 thione in dry dimethylformamide 8 ml was added to the above solution, and the mixture was allowed to react at room temperature for 14 hours. The reaction mixture was concentrated by evaporation under reduced pressure and the residue was subjected to silica gel column chromatography, eluted with chloroform methanol 50 1 , to give 292 mg 0.508 mmol of 1 2 3 3 methoxy 4 β methoxyethoxymethoxy phenyl 2 propenoyl aminoethyl 4 benzhydroxypiperidine. To a solution of 292 mg 0.508 mmol of the amide compound in methanol 8 ml was added 112 mg 0.589 mmol of p toluenesulfonic acid monohydrate, and the mixture was refluxed for 20 minutes. Water was added to the reaction mixture, which was adjusted to a pH value of 11 by the addition of an aqueous solution of sodium carbonate and then extracted with ethyl acetate. The organic layer was washed with water and concentrated by evaporation under reduced pressure. The residue was subjected to silica gel column chromatography, eluted with chloroform methanol 50 1 , to give 164 mg 0.337 mmol of 1 2 3 3 methoxy 4 hydroxyphenyl 2 propenoyl aminoethyl 4 benzhydroxypiperidine. Spectrophotometric data of the product support the structure shown below. 3300, 1660, 1620, 1600 To a solution of 228 mg 0.518 mmol of 1 2 phthaloylaminoethyl 4 benzhydroxypiperidine in ethanol 5 ml was added 50 mg 0.999 mmol of hydrazine hydrate, and the mixture was refluxed for 1 hour under argon atmosphere. The reaction mixture was concentrated by evaporation under reduced pressure and to the residue thus obtained was added 6 ml of dry dimethylformamide. To the solution was added 369 mg 0.892 mmol of N 3 3,5 dimethoxy 4 β methoxyethoxymethoxy phenyl 2 propenoyl thiazolidine 2 thione, and the mixture was allowed to react at room temperature for 40 hours. The reaction mixture was concentrated by evaporation under reduced pressure and the residue was subjected to silica gel column chromatography, eluted with chloroform methanol 50 1 , to give 276 mg 0.456 mmol of 1 2 3 3,5 dimethoxy 4 β methoxyethoxymethoxy phenyl 2 propenoyl aminoethyl 4 benzhydroxypiperidine. To a solution of 276 mg 0.456 mmol of the amide compound in methanol 6 ml was added 79 mg 0.415 mmol of p toluenesulfonic acid monohydrate, and the mixture was refluxed for 20 minutes. Water was added to the reaction mixture, which was adjusted to a pH value of 11 by the addition of an aqueous solution of sodium carbonate and then extracted with ethyl acetate. The organic layer was washed with water and concentrated by evaporation under reduced pressure. The residue was subjected to silica gel column chromatography, eluted with chloroform methanol 20 1 , to give 162 mg 0.299 mmol of 1 2 3 3,5 dimethoxy 4 hydroxyphenyl 2 propenoyl aminoethyl 4 benzhydroxypiperidine. Spectrophotometric data of the product support the structure shown below. 3400, 1660, 1620, 1600 To a solution of 777 mg 1.76 mmol of 1 2 phthaloylaminoethyl 4 benzhydroxypiperidine in ethanol 16 ml was added 148 mg 2.96 mmol of hydrazine hydrate, and the mixture was refluxed for 1 hour under argon atmosphere. The reaction mixture was concentrated by evaporation under reduced pressure. To the residue was added 4 ml of dry dimethylformamide, followed by the addition of a solution of 1.33 g 2.75 mmol of N 5 3,4 β methoxyethoxymethoxy phenyl 2,4 pentadienoyl thiazolidine 2 thione in dry dimethylformamide 10 ml and the mixture was allowed to react at room temperature for 14 hours. The reaction mixture was concentrated by evaporation under reduced pressure and the residue was subjected to silica gel column chromatography, eluted with chloroform methanol 50 1 , to give 500 mg 0.741 mmol of 1 2 5 3,4 bis β methoxyethoxymethoxy phenyl 2,4 pentadienoyl aminoethyl 4 benzhydroxypiperidine. To a solution of 500 mg 0.741 mmol of the amide compound in methanol 10 ml was added 144 mg 0.757 mmol of p toluenesulfonic acid monohydrate, and the mixture was refluxed for 35 minutes. Water was added to the reaction mixture, which was adjusted to a pH value of 11 by the addition of an aqueous solution of sodium carbonate, and then extracted with ethyl acetate. The organic layer was washed with water and concentrated by evaporation under reduced pressure. The residue was subjected to silica gel column chromatography, eluted with chloroform methanol 10 1 , to give 185 mg 0.353 mmol of 1 2 5 3,4 dihydroxyphenyl 2,4 pentadienoyl aminoethyl 4 benzhydroxypiperidine. 3300, 1650, 1590 1.67 2.93 10H, m , 3.57 3H, m , 5.60 1H, s , 6.25 1H, d, J 15Hz , 6.73 7.67 17H, m . To a solution of 508 mg 1.15 mmol of 1 2 phthaloylaminoethyl 4 benzhydroxypiperidine in ethanol 10 ml was added, under argon atmosphere 89 mg 1.78 mmol of hydrazine hydrate, and the mixture was refluxed for 1 hour. The reaction mixture was concentrated by evaporation under reduced pressure. To the residue was added 5 ml of dry dimethylformamide, followed by addition of a solution of 856 mg 2.11 mmol of N 5 3 methoxy 4 β methoxyethoxymethoxy phenyl 2,4 pentadienoyl thiazolidine 2 thione in dry dimethylformamide 5 ml and the mixture was reacted at room temperature for 1.5 hours. The reaction mixture was concentrated by evaporation under reduced pressure and the residue was subjected to silica gel column chromatography, eluted with chloroform methanol 50 1 , to give 690 mg 1.15 mmol of 1 2 5 3 methoxy 4 β methoxyethoxymethoxy phenyl 2,4 pentadienoyl aminoethyl 4 benzhydroxypiperidine. To a solution of 690 mg 1.15 mmol of the amide compound in methanol 14 ml was added 212 mg 1.12 mmol of p toluenesulfonic acid monohydrate, and the mixture was refluxed for 25 minutes. Water was added to the reaction mixture, which was adjusted to a pH value of 11 by the addition of an aqueous solution of sodium carbonate, and then extracted with ethyl acetate. The organic layer was washed with water and concentrated by evaporation under reduced pressure. The residue was subjected to silica gel column chromatography, eluted with chloroform methanol 50 1 , to give 393 mg 0.730 mmol of 1 2 5 3 methoxy 4 hydroxyphenyl 2,4 pentadienoyl aminoethyl 4 benzhydroxypiperidine. Spectrophotometric data of the product support the structure shown below. 3300, 1650, 1590 To a solution of 508 mg 1.15 mmol of 1 2 phthaloylaminoethyl 4 benzhydroxypiperidine in ethanol 10 ml was added, under argon atmosphere, 86 mg 1.72 mmol of hydrazine hydrate, and the mixture was refluxed for 1 hour. The reaction mixture was concentrated by evaporation under reduced pressure. To the residue was added 4 ml of dry dimethylformamide, followed by addition of a solution of 895 mg 2.04 mmol of N 5 3,5 dimethoxy 4 β methoxyethoxymethoxy phenyl 1 2,4 pentadienoyl thiazolidine 2 thione in dry dimethylformamide 6 ml , and the mixture was reacted at room temperature for 2 hours. The reaction mixture was concentrated by evaporation under reduced pressure and the residue was subjected to silica gel column chromatography, eluted with chloroform methanol 50 1 , to give 374 mg 0.593 mmol of 1 2 5 3,5 dimethoxy 4 β methoxyethoxymethoxy phenyl 2,4 pentadienoyl aminoethyl 4 benzhydroxypiperidine. To a solution of 374 mg 0.593 mmol of the amide compound in methanol 9 ml was added 120 mg 0.631 mmol of p toluenesulfonic acid monohydrate, and the mixture was refluxed for 30 minutes. Water was added to the reaction mixture, which was adjusted to a pH value of 11 by the addition of an aqueous solution of sodium carbonate, and then extracted with ethyl acetate. The organic layer was washed with water, concentrated by evaporation under reduced pressure, and the residue was subjected to silica gel column chromatography. There was obtained from fractions eluted with chloroform methanol 50 1 314 mg 0.552 mmol of 1 2 5 3,5 dimethoxy 4 hydroxyphenyl 2,4 pentadienoyl aminoethyl 4 benzhydroxypiperidine. Spectrophotometric data of the product support the structure shown below. 3350, 1610, 1590 In 10 ml of benzene were heated under reflux for 1 hour 5.36 g 20 mmol of N 3 bromopropyl phthalimide and 4.04 g 40 mmol of 4 hydroxypiperidine. To the reaction mixture was added water, and the mixture was extracted with n butanol. The organic layer was concentrated under reduced pressure, and the residue obtained was subjected to silica gel column chromatography. There was obtained from a fractions eluted with chloroform methanol 20 1 3.18 g 11.7 mmol of 1 3 phthaloylaminopropyl 4 hydroxypiperidine. In 10 ml of toluene were heated overnight under reflux in the presence of 3.45 g 25 mmol of potassium carbonate 3.18 g 11.7 mmol of the piperidine compound obtained above and 5.06 g 25 mmol of of benzhydryl chloride. To the reaction mixture was added water, and the mixture was extracted with chloroform. The chloroform layer was concentrated under reduced pressure, and the residue obtained was subjected to silica gel column chromatography. There was obtained from a fraction eluted with chloroform methanol 50 1 3.14 mg 6.92 mmol of 1 3 phthaloylaminopropyl 4 benzhydroxypiperidine. To a solution of 500 mg 1.10 mmol of the piperidine compound obtained above in 10 ml of ethanol was added in an argon atmosphere 138 mg 2.20 mmol of a 80 hydrazine hydrate. The mixture was heated under reflux for 2 hours and 30 minutes. To the residue obtained was added 10 ml of dimethylformamide. To the resulting solution was added a solution of 503 mg 1.10 mmol of N 3 3,4 di β methoxyethoxymethoxy phenyl 2 propenoyl thiazolidine 2 thione in N,N dimethylformamide solution 10 ml , and the mixture was reacted at room temperature for 15 hours. The reaction mixture was concentrated under reduced pressure. and the residue obtained was subjected to silica gel column chromatography. There was obtained from a fraction eluted with chloroform methanol 50 1 559 mg 0.84 mmol of 1 3 3 3,4 di β methoxyethoxymethoxy phenyl 2 propenoyl aminopropyl 4 benzhydroxypiperidine. To a solution of 559 mg 0.84 mmol of the amide compound obtained above in 12 ml of methanol was added 191 mg 1.01 mmol of p tolenesulfonic acid mono hydrate, and the mixture was heated under reflux for 20 minutes. To the reaction mixture was added saturated aqueous solution of bicarbonate solution to adjust the pH to 10, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and then concentrated under reduced pressure, and the residue obtained was subjected to silica gel column chromatography. There was obtained from a fraction eluted with chloroform methanol 100 9 323 mg 0.66 mmol of 1 3 3 3,4 dihydroxyphenyl 2 propenoyl aminopropyl 4 benzhydroxypiperidine. Spectrophotometric data of the product support the structure shown below. 3630, 3300, 1660, 1600 A solution of 7.34 g 72.6 mmol of 4 hydroxypiperidine and 10.3 g 36.5 mmol of N 4 bromobutyl phthalimide in 150 ml of benzene was refluxed in an argon atmosphere for 8 hours. To the reaction mixture, after cooled, was added water, and the resulting mixture was extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the residue obtained was subjected to silica gel column chromatography. There was obtained from a fraction eluted with chloroform methanol 20 1 7.91 g 26.2 mmol of 1 4 phthaloylaminobutyl 4 hydroxypiperidine. To 7.91 g 26.2 mmol of the alcohol compounds obtained above were added 10.0 ml 56.3 mmol of benzhydryl chloride and 4.36 g 31.6 mmol of potassium carbonate, and the resulting mixture was reacted at 135 To a solution of 356 mg 0.760 mmol of the piperidine compound obtained above in ethanol 7 ml was added 72 mg 1.15 mmol of hydrazine hydrate, and the mixture was refluxed for 1 hour in an argon atmosphere. To the residue obtained by concentration under reduced pressure was added dry dimethylformamide 3 ml . To the resulting mixture was further added a solution of 507 mg 1.32 mmol of N 3 3 methoxy 4 β methoxyethoxymethoxy phenyl 2 propenoyl thiazolidine 2 thione in dimethylformamide 5 ml , and the resulting mixture was reacted at room temperature for 4 hours. The residue obtained by concentration under reduced pressure was subjected to silica gel column chromatography. There was obtained from a fractions eluted with chloroform methanol 50 1 382 mg 0.634 mmol of 1 4 3 3 methoxy 4 β methoxyethoxymethoxy phenyl 2 propenoyl aminobutyl 4 benzhydroxypiperidine. To a solution of 382 mg 0.634 mmol of the amide compound obtained above in methanol 8 ml was added 125 mg 0.657 mmol of p toluenesulfonic acid mono hydrate, and the mixture was refluxed for 30 minutes. To the reaction mixture was added water, and the mixture was adjusted to pH 11 with an aqueous sodium carbonate solution and then extracted with ethyl acetate. The organic layer was washed with water and then concentrated under reduced pressure. The residue obtained was subjected to silica gel column chromatography. There was obtained from a fraction eluted with chloroform methanol 20 1 206 mg 0.400 mmol of 1 4 3 3 methoxy 4 hydroxyphenyl 2 propenoyl aminobutyl 4 benzhydroxypiperidine. Spectrophotometric data of the product support the structure shown below. 3350, 1660, 1600 To a solution of 454 mg 1 mmol of 1 3 phthaloylaminopropyl 4 benzhydroxypiperidine in 10 ml of ethanol was added in an argon atmosphere 125 mg 2 mmol of a 80 hydrazine hydrate, and the mixture was heated under reflux for 1 hour. The reaction mixture was concentrated under reduced pressure. To the residue obtained was added 10 ml of tetrahydrofuran. To the resulting solution was added a solution of 413 mg 1 mmol of N 3 3,4 dimethoxy 4 β methoxyethoxymethoxy phenyl 2 propenoyl thiazolidine 2 thione in tetrahydrofuran 10 ml , and the mixture was reacted at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue obtained was subjected to silica gel column chromatography. There was obtained from a fraction eluted with chloroform methanol 50 1 400 mg 0.65 mmol of 1 3 3 3,5 dimethoxy 4 β methoxyethoxymethoxy phenyl 2 propenoyl aminopropyl 4 benzhydroxypiperidine. To a solution of 400 mg 0.65 mmol of the amide compound obtained above in 10 ml of methanol was added 133 mg 0.7 mmol of p toluenesulfonic acid mono hydrate, and the resulting mixture was heated under reflux for 20 minutes. The reaction mixture was adjusted to pH 10 with saturated aqueous sodium bicarbonate solution and then extracted with chloroform. The chloroform layer was concentrated under reduced pressure, and the residue obtained was subjected to silica gel column chromatography. There was obtained from a fraction eluted with chloroform methanol 20 1 320 mg 0.60 mmol of 1 3 3 3,5 dimethoxy 4 hydroxyphenyl 2 propenoyl aminopropyl 4 benzhydroxypiperidine. Spectrophotometric data of the product support the structure shown below. 3300, 1660, 1620 To a solution of 367 mg 0.783 mmol of 1 4 phthaloylaminobutyl 4 benzhydroxypiperidine in ethanol 10 ml was added 75 mg 1.20 mmol of hydrazine hydrate, and the mixture was refluxed for 2 hours. To the residue obtained by concentration of the reaction mixture under reduced pressure was added 3 ml of dry dimethylformamide. To the residue was further added a solution of 751 mg 1.55 mmol of N 5 3,4 bis β methoxyethoxymethoxy phenyl 2,4 pentadienoyl thiazolidine 2 thione in dry dimethylformamide 6 ml , and the mixture was reacted at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, and the residue obtained was subjected to silica gel column chromatography. There was obtained from a fraction eluted with chloroform methanol 50 1 391 mg 0.556 mmol of 1 4 5 3,4 bis β methoxyethoxymethoxy phenyl 2,4 pentadienoyl aminobutyl 4 benzhydroxypiperidine. To a solution of 391 mg 0.556 mmol of the amide compound obtained above in methanol 10 ml was added 107 mg 0.563 mmol of p toluenesulfonic acid mono hydrate, and the mixture was refluxed for 1 hour. To the reaction mixture was added water, and the mixture was adjusted to pH 11 with an aqueous sodium carbonate solution and then extracted with ethyl acetate. The organic layer was washed with water and then concentrated under reduced pressure, and the residue obtained was subjected to silica gel column chromatography. There was obtained from a fraction eluted with chloroform methanol 10 1 149 mg 0.270 mmol of 1 4 5 3,4 dihydroxyphenyl 2,4 pentadienoyl aminobutyl 4 benzhydroxypiperidine. Spectrophotometric data of the product support the structure shown below. 3300, 1650, 1590 To a solution of 500 mg 1.10 mmol of 1 3 phthaloylaminopropyl 4 benzhydroxypiperidine in 10 ml of ethanol was added 138 mg 2.20 mmol of a 80 hydrazine hydrate in an argon atmosphere, and the solution was heated under reflux for 2 hours and 30 mintes. The reaction mixture was concentrated under reduced pressure. To the residue obtained was added 10 ml of N,N dimethylformamide. To the resulting solution was added a solution of 450 mg 1.10 mmol of N 5 3 methoxy 4 β methoxyethoxymethoxy phenyl 2,4 pentadienoyl thiazolidine 2 thione in N,N dimethylformamide 10 ml , and the mixture was reacted at room temperature for 15 hours. The reaction mixture was concentrated under reduced pressure, and the residue obtained was subjected to silica gel column chromatography. There was obtained from a fractions eluted with chloroform methanol 50 1 484 mg 0.79 mmol of 1 3 5 3 methoxy 4 β methoxyethoxymethoxy phenyl 2,4 pentadienoyl aminopropyl 4 benzhydroxypiperidine. To a solution of 484 mg 0.79 mmol of the amide compound obtained above in 12 ml of methanol was added 180 mg 0.95 mmol of p toluenesulfonic acid mono hydrate, and the mixture was heated under reflux for 30 minutes. The reaction mixture was adjusted to pH 10 with saturated aqueous sodium bicarbonate solution and then extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue obtained was subjected to silica gel column chromatography. There was obtained from a fraction eluted with chloroform methanol 20 1 408 mg 0.77 mmol of 1 3 5 3 methoxy 4 hydroxyphenyl 2,4 pentadienoyl aminopropyl 4 benzhydroxypiperidine. Spectrophotometric data of the product support the structure shown below. 3300, 1650, 1590 To a solution of 500 mg 1.07 mmol of 1 4 phthaloylaminobutyl 4 benzhydroxypiperidine in 10 ml of ethanol was added 134 mg 2.14 mmol of a 80 hydrazine hydrate, and the mixture was heated under reflux for 3 hours. The reaction mixture was concentrated under reduced pressure. To the residue obtained was added 10 ml of dimethylformamide. To the resulting solution was added a solution of 470 mg 1.07 mmol of N 5 3,5 dimethoxy 4 β methoxyethoxymethoxy phenyl 2,4 pentadienoyl thiazolidine 2 thione in N,N dimethylformamide 10 ml , and the mixture was reacted at room temperature for 15 hours. The reaction mixture was concentrated under reduced pressure, and the residue obtained was subjected to silica gel column chromatography. There was obtained from a fraction eluted with chloroform methanol 50 1 464 mg 0.70 mmol of 1 4 5 3,5 dimethoxy 4 β methoxyethoxymethoxy phenyl 2,4 pentadienoyl aminobutyl 4 benzhydroxypiperidine. To a solution of 464 mg 0.70 mmol of the amide compound obtained above in 12 ml of methanol was added 160 mg 0.84 mmol of p toluenesulfonic acid mono hydrate, and the mixture was heated under reflux for 20 minutes. The reaction mixture was adjusted to pH 10 with saturated aqueous sodium bicarbonate solution and then extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue obtained was subjected to silica gel column chromatography. There was obtained from a fraction eluted with chloroform methanol 20 1 298 mg 0.52 mmol of 1 4 5 3,5 dimethoxy 4 hydroxyphenyl 2,4 pentadienoyl aminobutyl 4 benzhydroxyp iperidine. Spectrophotometric data of the product support the structure shown below. 3630, 3540, 3450, 1660, 1620. Mouse mastcytoma cells P 815 are diluted in a culture solution, containing 90 Eagle Basic Medium manufactured by Gibco Laboratories to 5 x 10⁴ cells ml. The diluted solution is cultivated with shaking in air at 37 An acute toxicity test was run in ICR male mice 5 week old by oral administration. LD₅₀ s with all of the compounds of the invention were 100 mg kg body weight or higher, by which the high safety as compared with the efficacy was demonstrated.